According to the American Bar Association Journal, lawyers have filed exactly 131 cases against Boehringer Ingelheim, the global drug maker based in Germany, and one of the largest pharmaceutical companies in the world. These suits allege that Boehringer Ingelheim’s drug Pradaxa is a defective drug that has caused serious injuries and deaths among patients.
Pradaxa is used to prevent drug clots in patients with cardiac arrhythmia.
The problem with Pradaxa is it has been touted by Boehringer Ingelheim’s marketing and sales arm as a new-and-improved alternative to warfarin, a drug that has been on the market for decades. Doctors and health care professionals understand how to administer warfarin and minimize the risk associated with the drug.
Specifically, the Pradaxa lawsuits allege a failure to warn of risks, as well as Boehringer Ingelheim’s failure to provide an effective antidote in the case of a major bleeding event in a patient. As it has happened in some cases, bleeding caused by Pradaxa has been irreversible.
For its part, Boehringer Ingelheim cites a FDA report stating that Pradaxa is essentially no worse than warfarin. This may be true, but has little relation to Boehringer Ingelheim’s marketing and sales practices.